AAAAAA

   
Results: 1-14 |
Results: 14
Pseudomembranous tracheobronchitis due to Bacillus cereus
Authors: Strauss, R Mueller, A Wehler, M Neureiter, D Fischer, E Gramatzki, M Hahn, EG
Citation: R. Strauss et al., Pseudomembranous tracheobronchitis due to Bacillus cereus, CLIN INF D, 33(5), 2001, pp. E39-E41
FISH monitoring of 100 courses of human leukemias: The cytogenetic viewpoint
Authors: Gebhart, E Rosler, W Gramatzki, M Trautmann, U
Citation: E. Gebhart et al., FISH monitoring of 100 courses of human leukemias: The cytogenetic viewpoint, INT J ONCOL, 19(3), 2001, pp. 617-623
Comparative genomic hybridization-aided unraveling of complex karyotypes in human hematopoietic neoplasias
Authors: Verdorfer, I Brecevic, L Saul, W Schenker, B Kirsch, M Trautmann, U Helm, G Gramatzki, M Gebhart, E
Citation: I. Verdorfer et al., Comparative genomic hybridization-aided unraveling of complex karyotypes in human hematopoietic neoplasias, CANC GENET, 124(1), 2001, pp. 1-6
Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies
Authors: Stockmeyer, B Elsasser, D Dechant, M Repp, R Gramatzki, M Glennie, MJ van de Winkel, JGJ Valerius, T
Citation: B. Stockmeyer et al., Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies, J IMMUNOL M, 248(1-2), 2001, pp. 103-111
The IL-6 receptor antagonist SANT-7 overcomes bone marrow stromal cell-mediated drug resistance of multiple myeloma cells
Authors: Honemann, D Chatterjee, M Savino, R Bommert, K Burger, R Gramatzki, M Dorken, B Bargou, RC
Citation: D. Honemann et al., The IL-6 receptor antagonist SANT-7 overcomes bone marrow stromal cell-mediated drug resistance of multiple myeloma cells, INT J CANC, 93(5), 2001, pp. 674-680
IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastaticrenal cell carcinoma: long-term results of a controlled randomized clinical trial
Authors: Atzpodien, J Kirchner, H Illiger, HJ Metzner, B Ukena, D Schott, H Funke, PJ Gramatzki, M von Jurgensom, S Wandert, T Patzelt, T Reitz, M
Citation: J. Atzpodien et al., IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastaticrenal cell carcinoma: long-term results of a controlled randomized clinical trial, BR J CANC, 85(8), 2001, pp. 1130-1136
The 10.000/mu l morning trigger for prophylactic platelet transfusion is safe: Prospective experience in 411 AML patients
Authors: Wandt, H Frank, M Denzel, T Aulitzky, W Bodenstein, H Brack, N Duerk, H Engberding, R Fauser, A Geer, T Germann, B Gramatzki, M Kaesberger, J Kisro, J Knigge, O Kochling, G Kuse, R Link, H Neubauer, A Ohl, S Pfluger, R Saal, J Schakel, U Schalk, K Schmidt, H Soucek, S Wagner, T Wilms, K Winter, R Ehninger, G
Citation: H. Wandt et al., The 10.000/mu l morning trigger for prophylactic platelet transfusion is safe: Prospective experience in 411 AML patients, HEMAT BLOOD, 40, 2001, pp. 488-490
IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group
Authors: Feuring-Buske, M Kneba, M Unterhalt, M Engert, A Gramatzki, M Hiller, E Trumper, L Brugger, W Ostermann, H Atzpodien, J Hallek, M Aulitzky, E Hiddemann, W
Citation: M. Feuring-buske et al., IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group, ANN HEMATOL, 79(9), 2000, pp. 493-500
Triggering FC alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy
Authors: Stockmeyer, B Dechant, M van Egmond, M Tutt, AL Sundarapandiyan, K Graziano, RF Repp, R Kalden, JR Gramatzki, M Glennie, MJ van de Winkel, JGJ Valerius, T
Citation: B. Stockmeyer et al., Triggering FC alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy, J IMMUNOL, 165(10), 2000, pp. 5954-5961
Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies
Authors: Behr, TM Wormann, B Gramatzki, M Riggert, J Gratz, S Behe, M Griesinger, F Sharkey, RM Kolb, HJ Hiddemann, W Goldenberg, DM Becker, W
Citation: Tm. Behr et al., Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies, CLIN CANC R, 5(10), 1999, pp. 3304S-3314S
Differential expression of alpha 2-6 sialylated polylactosamine structuresby human B and T cells
Authors: Kniep, B Schakel, K Nimtz, M Schwartz-Albiez, R Schmitz, M Northoff, H Vilella, R Gramatzki, M Rieber, EP
Citation: B. Kniep et al., Differential expression of alpha 2-6 sialylated polylactosamine structuresby human B and T cells, GLYCOBIOLOG, 9(4), 1999, pp. 399-406
Preclinical studies combining bispecific antibodies with cytokine-stimulated effector cells for immunotherapy of renal cell carcinoma
Authors: Elsasser, D Stadick, H Stark, S Van de Winkel, JGJ Gramatzki, M Schrott, KM Valerius, T Schafhauser, W
Citation: D. Elsasser et al., Preclinical studies combining bispecific antibodies with cytokine-stimulated effector cells for immunotherapy of renal cell carcinoma, ANTICANC R, 19(2C), 1999, pp. 1525-1528
Heterogeneity of T-acute lymphoblastic leukemia (T-ALL) cell lines: Suggestion for classification by immunophenotype and T-cell receptor studies
Authors: Burger, R Hansen-Hagge, TE Drexler, HG Gramatzki, M
Citation: R. Burger et al., Heterogeneity of T-acute lymphoblastic leukemia (T-ALL) cell lines: Suggestion for classification by immunophenotype and T-cell receptor studies, LEUK RES, 23(1), 1999, pp. 19-27
Intralymphatic interleukin-2 in combination with zidovudine for the therapy of patients with AIDS
Authors: Harrer, T Schwab, J Struff, WG Schmitt, M Ficker, JH Rodl, W Parsch, H Kalden, JR Gramatzki, M
Citation: T. Harrer et al., Intralymphatic interleukin-2 in combination with zidovudine for the therapy of patients with AIDS, INFECTION, 26(6), 1998, pp. 368-374
Risultati: 1-14 |